Immunneuropathien

  • Mathias Mäurer
  • Reinhard Kiefer
  • Hermann Müller-Vahl
  • Carsten Wessig
Chapter

Zusammenfassung

Bei den Immunneuropathien können akute Verläufe von chronischen Erkrankungen abgegrenzt werden. In der Regel erreichen akute Immunneuropathien ihr Krankheitsmaximum innerhalb von 4–6 Wochen; alle Verläufe, die über einen Zeitraum von 8 Wochen progredient sind, sollten an eine chronische Immunneuropathie denken lassen. Zu den akuten immunvermittelten Neuropathien zählen das Guillain-Barré-Syndrom (GBS) einschließlich seiner axonalen Subtypen, das Miller-Fisher-Syndrom (MFS), die Polyneuritis cranialis und die sehr seltene akute Pandysautonomie. Die wichtigste chronische Immunneuropathie ist die chronisch inflammatoriche Polyneuropathie (CIDP). Zu den chronischen Immunneuropathien zählt außerdem die multifokal motorische Neuropathie (MMN). In diesem Kapitel wird auch die neuralgische Amyotrophie abgehandelt, eine Gruppe schwerwiegender akuter oder subakuter fokaler peripherer Nervenschäden, denen im Einzelnen noch nicht aufgeklärte krankhafte Autoimmunvorgänge zugrunde liegen.

Literatur

Literatur zu Abschnitt 2.1

  1. Berg B van den, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Doorn PA van (2014) Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10(8):469–482CrossRefGoogle Scholar
  2. Doorn PA van, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7:939–950CrossRefGoogle Scholar
  3. Fisher M (1956) An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255:57–65CrossRefGoogle Scholar
  4. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome (1987) Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22:753–761CrossRefGoogle Scholar
  5. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome (1992) Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 32:94–97CrossRefGoogle Scholar
  6. Garssen MP, Koningsveld R van, Doorn PA van, Merkies IS, Scheltens-de Boer M, Leusden JA van, Schaik IN van, Linssen WH, Visscher F, Boon AM, Faber CG, Meulstee J, Prick MJ, Berg LH van den, Franssen H, Hiel JA, Bergh PY van den, Sindic CJ (2007) Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry 78(9):1012–1013CrossRefGoogle Scholar
  7. Guillain G, Barré J, Strohl A (1916) Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalorachidien sans reaction celluaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Med Hop Paris 28:1462–1470Google Scholar
  8. Guillain-Barre Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 341:586–590Google Scholar
  9. Hahn K, Husstedt IW, Arendt G für die Deutsche Neuro-AIDS-Arbeitsgemeinschaft (DNAA) (2010) HIV-associated neuropathies. Nervenarzt 81:409–417CrossRefGoogle Scholar
  10. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (1995) Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118:597–605CrossRefGoogle Scholar
  11. Hughes RA, Brassington R, Gunn AA, Doorn PA van (2016) Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016 Oct 24;10:CD001446Google Scholar
  12. Koningsveld R van, Schmitz PI, Ang CW, Groen J, Osterhaus AD, Meche FG van der, Doorn PA van (2002) Infections and course of disease in mild forms of Guillain-Barre syndrome. Neurology 58:610–614CrossRefGoogle Scholar
  13. Koningsveld R van, Schmitz PI, Meché FG, Visser LH, Meulstee J, Doorn PA van, Dutch GBS study group (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363(9404):192–196CrossRefGoogle Scholar
  14. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, Clark S, Haber P, Stolley PD, Schonberger LB, Chen RT (1998) The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 339:1797–1802CrossRefGoogle Scholar
  15. Meche FGA van der, Schmitz PIM, and the Dutch Guillain-Barre study group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326:1123–1129CrossRefGoogle Scholar
  16. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group (1997) Comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barre syndrome. Lancet 349:225–230CrossRefGoogle Scholar
  17. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, Willison HJ, Winer JB, Hughes RA (2003) A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 61:1282–1284CrossRefGoogle Scholar
  18. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71(2):235–238CrossRefGoogle Scholar
  19. The Guillain-Barre study group (1985) Plasmapheresis and acute Guillain-Barre syndrome. Neurology 35:1096–1104CrossRefGoogle Scholar
  20. Wang Y, Zhang HL, Wu X, Zhu J (2016) Complications of Guillain-Barré syndrome. Expert Rev Clin Immunol 12(4):439–448CrossRefGoogle Scholar
  21. Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barré syndrome. Lancet 388(10045):717–727CrossRefGoogle Scholar

Literatur zu Abschnitt 2.2

  1. Cats EA, Pol WL van der, Piepers S (2010) Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 75:818–825CrossRefGoogle Scholar
  2. Dispenzieri A (2015) POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol 90:951–962CrossRefGoogle Scholar
  3. Eftimov F, Winer JB, Vermeulen M, Haan R de, Schaik IN van (2013) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev:CD001797Google Scholar
  4. Hadden RD, Nobile-Orazio E, Sommer C et al (2006) European federation of neurological societies/peripheral nerve society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13:809–818CrossRefGoogle Scholar
  5. Hahn AF, Beydoun SR, Lawson V, IVIG in MMN Study Team, Oh M, Empson VG, Leibl H, Ngo LY, Gelmont D, Koski CL (2013) A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 18:321–330CrossRefGoogle Scholar
  6. Hughes RA, Mehndiratta MM (2015) Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev.:CD002062Google Scholar
  7. Hughes RA, Donofrio P, Bril V et al (2008) Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136–144CrossRefGoogle Scholar
  8. Joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society (2010) European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society-first revision. J Peripher Nerv Syst 15:1–9Google Scholar
  9. Kyle RA, Durie BG, Rajkumar SV et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121–1127CrossRefGoogle Scholar
  10. Latov N (2014) Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 10:435–446CrossRefGoogle Scholar
  11. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Vial C, Steck A, Musset L, Marin B, RIMAG Study Group (France and Switzerland) (2013) Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology 80:2217–2225CrossRefGoogle Scholar
  12. Léger JM, Guimarães-Costa R, Ferfoglia RI (2015) The pathogenesis of multifocal motor neuropathy and an update on current management options. Ther Adv Neurol Disord 8:109–122CrossRefGoogle Scholar
  13. Lunn MP, Nobile-Orazio E (2012) Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev.:CD002827Google Scholar
  14. Nobile-Orazio E, Gallia F (2013) Multifocal motor neuropathy: current therapies and novel strategies. Drugs 73:397–406CrossRefGoogle Scholar
  15. Olney RK, Lewis RA, Putnam TD, Campellone JV Jr (2003) Consensus criteria for the diagnosis of multifocal motor neuropathy. Muscle Nerve 27:117–121CrossRefGoogle Scholar
  16. Raheja D, Specht C, Simmons Z (2015) Paraproteinemic neuropathies. Muscle Nerve 51:1–13CrossRefGoogle Scholar
  17. Schaik IN van, Bouche P, Illa I (2006) European federation of neurological societies/peripheral nerve society guideline on management of multifocal motor neuropathy. Eur J Neurol 13:802–808CrossRefGoogle Scholar
  18. Stork AC, Lunn MP, Nobile-Orazio E, Notermans NC (2015) Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev.:CD005376Google Scholar
  19. Vallat JM, Magy L, Ciron J, Corcia P, Le Masson G, Mathis S (2016) Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies. Expert Rev Neurother 16(9):1111–1119CrossRefGoogle Scholar

Literatur zu Abschnitt 2.3

  1. Abraham A, Izenberg A, Dodig D, Bril V, Breiner A (2016) Peripheral nerve ultrasound imaging shows enlargement of peripheral nerves outside the brachial plexus in neuralgic amyotrophy. J Clin Neurophysiol 33:e31–e33CrossRefGoogle Scholar
  2. Alfen N van, Engelen BG van (2006) The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain 129(Pt 2):438–450CrossRefGoogle Scholar
  3. Alfen N van, Eijk JJ van, Ennik T, Flynn SO, Nobacht IE, Groothuis JT, Pillen S, Laar FA van de (2015) Incidence of neuralgic amyotrophy (Parsonage Turner syndrome) in a primary care setting – a prospective cohort study. PLoS One 10(5):e0128361.  https://doi.org/10.1371/journal.pone.0128361. eCollection 2015CrossRefGoogle Scholar
  4. Arányi Z, Csillik A, Dévay K, Rosero M, Barsi P, Böhm J, Schelle T (2015) Ultrasonographic identification of nerve pathology in neuralgic amyotrophy: enlargement, constriction, fascicular entwinement, and torsion. Muscle Nerve 52:503–511CrossRefGoogle Scholar
  5. Bäumer P, Kele H, Xia A, Weiler M, Schwarz D, Bendszus M, Pham M (2016) Posterior interosseous neuropathy: supinator syndrome vs fascicular radial neuropathy. Neurology 87:1884–1891CrossRefGoogle Scholar
  6. Cup EH, Ijspeert J, Janssen RJ, Bussemaker-Beumer C, Jacobs J, Pieterse AJ, Linde H van der, Alfen N van (2013) Residual complaints after neuralgic amyotrophy. Arch Phys Med Rehabil 94:67–73CrossRefGoogle Scholar
  7. Eijk JJ van, Groothuis JT, Alfen N van (2016) Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment. Muscle Nerve 53:337–350CrossRefGoogle Scholar
  8. Ferrante MA, Wilbourn AJ (2017) Lesion distribution among 281 patients with sporadic neuralgic amyotrophy. Muscle Nerve 55:858–861CrossRefGoogle Scholar
  9. Lieba-Samal D, Jengojan S, Kasprian G, Wöber C, Bodner G (2016) Neuroimaging of classic neuralgic amyotrophy. Muscle Nerve 54:1079–1085CrossRefGoogle Scholar
  10. Lundborg G (2003) Commentary: hourglass-like fascicular nerve compressions. J Hand Surg Am 28:212–214CrossRefGoogle Scholar
  11. Maldonado AA, Amrami KK, Mauermann ML, Spinner RJ (2017) Nontraumatic „isolated“ posterior interosseous nerve palsy: Reinterpretation of electrodiagnostic studies and MRIs. J Plast Reconstr Aesthet Surg 70:159–165CrossRefGoogle Scholar
  12. Müller-Vahl H, Mumenthaler M, Stöhr M, Tegenthoff M (Hrsg) (2014) Läsionen peripherer Nerven und radikuläre Syndrome, 10. Aufl. Thieme, StuttgartGoogle Scholar
  13. Pan Y, Wang S, Zheng D, Tian W, Tian G, Ho PC, Cheng HS, Zhong Y (2014) Hourglass-like constrictions of peripheral nerve in the upper extremity: a clinical review and pathological study. Neurosurgery 75:10–22CrossRefGoogle Scholar
  14. Parsonage MJ, Turner JW (1948) Neuralgic amyotrophy; the shoulder-girdle syndrome. Lancet 1(6513):973–978CrossRefGoogle Scholar
  15. Pham M, Bäumer P, Meinck HM, Schiefer J, Weiler M, Bendszus M, Kele H (2014) Anterior interosseous nerve syndrome: fascicular motor lesions of median nerve trunk. Neurology 82:598–606CrossRefGoogle Scholar
  16. Staff NP, Engelstad J, Klein CJ, Amrami KK, Spinner RJ, Dyck PJ, Warner MA, Warner ME, Dyck PJ (2010) Post-surgical inflammatory neuropathy. Brain 133:2866–2880CrossRefGoogle Scholar
  17. Sunagawa T, Nakashima Y, Shinomiya R, Kurumadani H, Adachi N, Ochi M (2017) Correlation between „hourglass-like fascicular constriction“ and idiopathic anterior interosseous nerve palsy. Muscle Nerve 55:508–551CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Mathias Mäurer
    • 2
  • Reinhard Kiefer
    • 1
  • Hermann Müller-Vahl
    • 3
  • Carsten Wessig
    • 4
  1. 1.Rotenburg(Wümme)Deutschland
  2. 2.WürzburgDeutschland
  3. 3.HannoverDeutschland
  4. 4.Bad KissingenDeutschland

Personalised recommendations